Bristol-Myers Squibb Co., of New York, said it has completed the acquisition of Padlock Therapeutics Inc., which includes full rights to their protein/peptidyl arginine deiminase (PAD) inhibitor discovery program focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis and other autoimmune diseases.